Evidence map›Paper›PMID 40237455›Full record

ReviewmBio2025

Public antibodies: convergent signatures in human humoral immunity against pathogens.

Vishal N Rao, Camila H Coelho

Abstract readReview
In one paragraph

Review in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Is the vaccination-induced B cell receptor repertoire predictable?Immunoinformatics (Amsterdam, Netherlands) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Vishal N RaoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0000-0002-1092-1001
Camila H CoelhoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0000-0002-7885-9996

Funding

NIH FIRST Cohort Cluster Hiring Initiative at Icahn School of Medicine at Mount SinaiU54CA267776 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Nihal Mohamed · 2021 to 2026
$17.4M
UC San Diego RAPID Faculty Development Program in Infectious DiseasesR25AI147376 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ADRIANA H TREMOULET, Joann Trejo · 2020 to 2026
$2.5M
NCI NIH HHS U54 CA267776NIAID NIH HHS R25 AI147376NIH HHS U54CA267776
6 · The paper itself

Abstract

The human humoral immune system has evolved to recognize a vast array of pathogenic threats. This ability is primarily driven by the immense diversity of antibodies generated by gene rearrangement during B cell development. However, different people often produce strikingly similar antibodies when exposed to the same antigen-known as public antibodies. Public antibodies not only reflect the immune system's ability to consistently select for optimal B cells but can also serve as signatures of the humoral responses triggered by infection and vaccination. In this Minireview, we examine and compare public antibody identification methods, including the identification criteria used based on V(D)J gene usage and similarity in the complementarity-determining region three sequences, and explore the molecular features of public antibodies elicited against common pathogens, including viruses, protozoa, and bacteria. Finally, we discuss the evolutionary significance and potential applications of public antibodies in informing the design of germline-targeting vaccines, predicting escape mutations in emerging viruses, and providing insights into the process of affinity maturation. The ongoing discovery of public antibodies in response to emerging pathogens holds the potential to improve pandemic preparedness, accelerate vaccine design efforts, and deepen our understanding of human B cell biology.

Indexed as

AntibodiesImmunity, HumoralAntibodies, ViralB-LymphocytesHumansVirusesAntibodiesAntibodies, Viralantibody repertoirehuman pathogenspublic antibodiessomatic hypermutationV(D)J recombination

Identifiers

PMID40237455
PMCPMC12077206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.